Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cetuximab 5Irinotecan 3Gemcitabine 2tivozanib 1neratinib 1lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Secretin 1Paclitaxel 1PX-866 1Oxaliplatin 1Lomustine 1Leucovorin 1Fluorouracil 1Doxorubicin 1Carboplatin 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × CB-839 × Gastrointestinal × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡